Affinity Asset Advisors, LLC
- SEC CIK
- 0001773195
- Latest filing
- Aug 13, 2026
Holdings in Q1 2026
Holdings as of Mar 31, 2026, filed May 14, 2026. Long positions only; changes compare share counts with Q4 2025.
- Positions
- 95
- +9 vs. Q4 2025
- Portfolio value
- $1.71B
- +$313.3M (+22.5%) vs. Q4 2025
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| APGEApogee Therapeutics, Inc. | COM | 1,284,926 | $108.2M | 6.3% | +50,000+4.0% | Added | History |
| XENEXenon Pharmaceuticals Inc. | COM | 1,675,000 | $97.4M | 5.7% | +425,000+34.0% | Added | History |
| ERASErasca, Inc. | COM | 5,350,000 | $86.6M | 5.1% | +1,450,000+37.2% | Added | History |
| INSMINSMED Inc | COM PAR $.01 | 480,000 | $78.5M | 4.6% | +30,000+6.7% | Added | History |
| ROIVRoivant Sciences Ltd. | SHS | 2,800,000 | $77.6M | 4.5% | +1,100,000+64.7% | Added | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 1,279,134 | $64.5M | 3.8% | −153,457−10.7% | Reduced | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 1,400,000 | $55.6M | 3.3% | +799,448+133.1% | Added | History |
| PRAXPraxis Precision Medicines, Inc. | COM NEW | 170,000 | $54.8M | 3.2% | −15,000−8.1% | Reduced | History |
| ANABAnaptysbio, Inc | COM | 940,000 | $52.1M | 3.1% | +495,308+111.4% | Added | History |
| ALKSAlkermes plc. | SHS | 1,350,000 | $47.7M | 2.8% | +350,000+35.0% | Added | History |
| CYTKCytokinetics Inc | COM NEW | 700,483 | $46.2M | 2.7% | −99,517−12.4% | Reduced | History |
| ABVXAbivax S.A. | SPONSORED ADS | 405,000 | $45.1M | 2.6% | −100,000−19.8% | Reduced | History |
| TEVATeva Pharmaceutical Industries Ltd | SPONSORED ADS | 1,400,000 | $42.2M | 2.5% | 00.0% | Unchanged | History |
| ACLXArcellx, Inc. | COMMON STOCK | 362,764 | $41.7M | 2.4% | −160,961−30.7% | Reduced | History |
| NUVLNuvalent, Inc. | COM | 300,000 | $30.7M | 1.8% | −22,633−7.0% | Reduced | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 562,631 | $29.7M | 1.7% | +12,631+2.3% | Added | History |
| DNTHDianthus Therapeutics, Inc. | COM | 350,000 | $29.4M | 1.7% | +235,000+204.3% | Added | History |
| LXEOLexeo Therapeutics, Inc. | COM | 5,050,211 | $29.0M | 1.7% | +1,850,211+57.8% | Added | History |
| COGTCogent Biosciences, Inc. | COM | 750,000 | $28.9M | 1.7% | +400,000+114.3% | Added | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 55,000 | $28.8M | 1.7% | +23,869+76.7% | Added | History |
| STROSutro Biopharma, Inc. | COM SHS | 1,069,519 | $26.6M | 1.6% | +321,137+42.9% | Added | History |
| FBRXForte Biosciences, Inc. | COM NEW | 1,011,890 | $26.2M | 1.5% | +22,400+2.3% | Added | History |
| ORKAOruka Therapeutics, Inc. | COM | 499,673 | $24.5M | 1.4% | −302,669−37.7% | Reduced | History |
| TRVITrevi Therapeutics, Inc. | COM | 2,000,172 | $23.9M | 1.4% | −150,000−7.0% | Reduced | History |
| OVIDOvid Therapeutics Inc. | COM | 10,636,318 | $23.6M | 1.4% | +3,486,318+48.8% | Added | History |
| ELVNEnliven Therapeutics, Inc. | COM | 586,904 | $23.0M | 1.3% | +586,904 | New | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 95,000 | $21.7M | 1.3% | +65,000+216.7% | Added | History |
| MLYSMineralys Therapeutics, Inc. | COM | 750,000 | $20.3M | 1.2% | +20,000+2.7% | Added | History |
| AVTXAvalo Therapeutics, Inc. | COM NEW | 1,340,840 | $20.0M | 1.2% | +289,786+27.6% | Added | History |
| PTGXProtagonist Therapeutics, Inc | COM | 172,125 | $18.1M | 1.1% | 00.0% | Unchanged | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 500,000 | $15.9M | 0.9% | +150,000+42.9% | Added | History |
| ZURAZura Bio Ltd | CLASS A ORD SHS | 2,564,303 | $15.3M | 0.9% | +750,632+41.4% | Added | History |
| NRIXNurix Therapeutics, Inc. | COM | 967,620 | $15.0M | 0.9% | 00.0% | Unchanged | History |
| SVRASavara Inc | COM | 2,512,153 | $13.7M | 0.8% | −285,000−10.2% | Reduced | History |
| Omeros Corp682143AK8 | NOTE 9.500% 6/1 | – | $13.2M | 0.8% | – | – | – |
| CATXPerspective Therapeutics, Inc. | COM NEW | 3,164,582 | $13.2M | 0.8% | +2,864,582+954.9% | Added | History |
| HLXCHelix Acquisition Corp. III | USD CL A ORD SHS | 1,250,000 | $12.7M | 0.7% | +1,250,000 | New | History |
| ARWRArrowhead Pharmaceuticals, Inc. | COM | 200,000 | $12.5M | 0.7% | +130,000+185.7% | Added | History |
| DMRADamora Therapeutics, Inc. | COM NEW | 450,000 | $11.7M | 0.7% | +450,000 | New | History |
| EPRXEupraxia Pharmaceuticals Inc. | COM | 1,589,005 | $11.5M | 0.7% | +1,289,005+429.7% | Added | History |
| ANROAlto Neuroscience, Inc. | COM SHS | 500,000 | $11.2M | 0.7% | +500,000 | New | History |
| BBIOBridgeBio Pharma, Inc. | COM | 150,000 | $11.1M | 0.7% | −170,000−53.1% | Reduced | History |
| CGEMCullinan Therapeutics, Inc. | COM | 781,260 | $11.1M | 0.7% | −1,150,846−59.6% | Reduced | History |
| BLTEBelite Bio, Inc | SPONSORED ADS | 65,000 | $10.4M | 0.6% | +45,000+225.0% | Added | History |
| WVEWave Life Sciences, Inc. | SHS | 1,401,727 | $10.2M | 0.6% | −1,298,273−48.1% | Reduced | History |
| VERAVera Therapeutics, Inc. | CL A | 250,000 | $10.1M | 0.6% | 00.0% | Unchanged | History |
| TYRATyra Biosciences, Inc. | COM | 257,512 | $9.86M | 0.6% | +257,512 | New | History |
| RVMDRevolution Medicines, Inc. | COM | 100,000 | $9.72M | 0.6% | 00.0% | Unchanged | History |
| JBIOJade Biosciences, Inc. | COM NEW | 639,956 | $8.99M | 0.5% | −75,000−10.5% | Reduced | History |
| TVTXTravere Therapeutics, Inc. | COM | 300,000 | $8.91M | 0.5% | 00.0% | Unchanged | History |
| NAMSNewAmsterdam Pharma Co N.V. | ORDINARY SHARES | 275,000 | $8.80M | 0.5% | 00.0% | Unchanged | History |
| Cogent Biosciences, Inc.19240QAA0 | NOTE 1.625%11/1 | – | $8.59M | 0.5% | – | – | – |
| KRROKorro Bio, Inc. | COM | 706,904 | $8.00M | 0.5% | +706,904 | New | History |
| Celcuity Inc.15102KAA8 | NOTE 2.750% 8/0 | – | $7.31M | 0.4% | – | – | – |
| CRSPCRISPR Therapeutics AG | NAMEN AKT | 150,000 | $7.14M | 0.4% | +150,000 | New | History |
| SGPSpyGlass Pharma, Inc. | COM SHS | 250,000 | $6.48M | 0.4% | +250,000 | New | History |
| CMPSCOMPASS Pathways plc | SPONSORED ADS | 1,108,483 | $6.13M | 0.4% | +908,483+454.2% | Added | History |
| IBIOiBio, Inc. | COM NEW | 3,107,200 | $5.90M | 0.3% | +1,050,000+51.0% | Added | History |
| ESTAEstablishment Labs Holdings Inc. | COM | 100,000 | $5.68M | 0.3% | −100,000−50.0% | Reduced | History |
| AVRAnteris Technologies Global Corp. | COM | 912,397 | $5.06M | 0.3% | +425,713+87.5% | Added | History |
| NAMSWNewAmsterdam Pharma Co N.V. | *W EXP 11/22/202 | 245,000 | $4.91M | 0.3% | 00.0% | Unchanged | History |
| VRDNViridian Therapeutics, Inc. | COM | 250,000 | $4.89M | 0.3% | 00.0% | Unchanged | History |
| CLYMClimb Bio, Inc. | COM | 700,000 | $4.79M | 0.3% | −600,000−46.2% | Reduced | History |
| RZLTRezolute, Inc. | COM NEW | 1,547,641 | $4.72M | 0.3% | −803,503−34.2% | Reduced | History |
| SGMTSagimet Biosciences Inc. | COM SER A | 868,020 | $4.54M | 0.3% | −280,225−24.4% | Reduced | History |
| MBXMBX Biosciences, Inc. | COM | 150,000 | $4.48M | 0.3% | −100,000−40.0% | Reduced | History |
| TSHATaysha Gene Therapies, Inc. | COM SHS | 1,000,000 | $4.47M | 0.3% | −2,300,000−69.7% | Reduced | History |
| MANEVeradermics, Inc | COMMON STOCK | 70,000 | $4.42M | 0.3% | +70,000 | New | History |
| GENBGenerate Biomedicines, Inc. | COM SHS | 350,000 | $4.38M | 0.3% | +350,000 | New | History |
| ENGNenGene Therapeutics Inc. | COM | 610,370 | $4.16M | 0.2% | −33,000−5.1% | Reduced | History |
| AVBPArriVent BioPharma, Inc. | COM | 175,000 | $4.04M | 0.2% | +25,000+16.7% | Added | History |
| RLAYRelay Therapeutics, Inc. | COM | 400,000 | $3.98M | 0.2% | +400,000 | New | History |
| PRQRProQR Therapeutics N.V. | SHS EURO | 2,454,278 | $3.98M | 0.2% | 00.0% | Unchanged | History |
| VRCAVerrica Pharmaceuticals Inc. | COM SHS | 707,338 | $3.74M | 0.2% | 00.0% | Unchanged | History |
| DTILPrecision Biosciences Inc | COM NEW | 597,946 | $3.29M | 0.2% | +597,946 | New | History |
| KPTIKaryopharm Therapeutics Inc. | COM NEW | 500,000 | $2.79M | 0.2% | −389,575−43.8% | Reduced | History |
| SLGLSol-Gel Technologies Ltd. | SHS NEW | 35,000 | $2.77M | 0.2% | +35,000 | New | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 75,000 | $2.72M | 0.2% | 00.0% | Unchanged | History |
| OACCUOaktree Acquisition Corp. III Life Sciences | UNIT 10/04/2029 | 250,000 | $2.66M | 0.2% | 00.0% | Unchanged | History |
| NXTCNextCure, Inc. | COM NEW | 241,826 | $2.58M | 0.2% | −5,468−2.2% | Reduced | History |
| IMVTImmunovant, Inc. | COM | 100,000 | $2.48M | 0.1% | −100,000−50.0% | Reduced | History |
| EQEquillium, Inc. | COM | 1,226,310 | $2.45M | 0.1% | +1,226,310 | New | History |
| SABSSAB Biotherapeutics, Inc. | COM NEW | 575,000 | $2.20M | 0.1% | +575,000 | New | History |
| CORTCorcept Therapeutics Inc | COM | 50,000 | $2.02M | 0.1% | +50,000 | New | History |
| OBIOOrchestra BioMed Holdings, Inc. | COM | 402,550 | $1.71M | 0.1% | −170,254−29.7% | Reduced | History |
| KZRKezar Life Sciences, Inc. | COM | 229,076 | $1.70M | 0.1% | 00.0% | Unchanged | History |
| MGNXMacrogenics Inc | COM | 500,000 | $1.45M | 0.1% | +15,692+3.2% | Added | History |
| ANLAdlai Nortye Group Ltd. | ADS | 164,748 | $1.14M | 0.1% | +164,748 | New | History |
| ALECAlector, Inc. | COM | 500,000 | $1.07M | 0.1% | +500,000 | New | History |
| OKUROnKure Therapeutics, Inc. | COM CL A | 240,963 | $997.6K | 0.1% | +240,963 | New | History |
| LENZLENZ Therapeutics, Inc. | COM | 100,000 | $915.0K | 0.1% | +100,000 | New | History |
| XFORX4 Pharmaceuticals, Inc | COM NEW | 145,000 | $598.9K | <0.1% | 00.0% | Unchanged | History |
| QTTBQ32 Bio Inc. | COM | 27,777 | $178.3K | <0.1% | 00.0% | Unchanged | History |
| ADGMAdagio Medical Holdings, Inc. | COM | 80,000 | $92.0K | <0.1% | 00.0% | Unchanged | History |
| Rocket Pharmaceuticals, Inc.77313F114 | *W EXP 09/02/202 | 75,000 | $1.18K | <0.1% | 00.0% | Unchanged | – |
Options (10)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| SPYSPDR S&P 500 ETF Trust | ETF | $130.1M | – |
| MRNAModerna, Inc. | Stock | – | $40.6M |
| BMYBristol Myers Squibb Co | Stock | – | $18.2M |
| RVMDRevolution Medicines, Inc. | COM | $9.72M | – |
| IBRXImmunityBio, Inc. | COM | $9.59M | – |
| NVONovo Nordisk A S | ADR | – | $6.43M |
| QUREuniQure N.V. | SHS | – | $4.91M |
| DNTHDianthus Therapeutics, Inc. | COM | – | $4.20M |
| CGONCG Oncology, Inc. | COM | – | $4.06M |
| CELCCelcuity Inc. | COM | – | $3.42M |
Sold out since Q4 2025 (11)
Positions held at the end of Q4 2025 that are gone from this filing.
| Security | Class | Shares in Q4 2025 | Value in Q4 2025 | % of portfolio in Q4 2025 | History |
|---|---|---|---|---|---|
| VTYXVentyx Biosciences, Inc. | COM | 6,484,558 | $58.6M | 4.2% | History |
| Travere Therapeutics, Inc.89422GAA5 | NOTE 2.250% 3/0 | – | $9.99M | 0.7% | – |
| TNGXTango Therapeutics, Inc. | COM | 1,000,000 | $8.86M | 0.6% | History |
| RCUSArcus Biosciences, Inc. | COM | 300,000 | $7.15M | 0.5% | History |
| AVDLAvadel Pharmaceuticals PLC | Stock | 250,000 | $5.39M | 0.4% | History |
| AMGNAmgen Inc | Stock | 10,000 | $3.27M | 0.2% | History |
| MRSNMersana Therapeutics, Inc. | COMMON STOCK | 100,000 | $2.89M | 0.2% | History |
| GERNGeron Corp | COM | 1,500,000 | $1.98M | 0.1% | History |
| RAREUltragenyx Pharmaceutical Inc. | COM | 75,000 | $1.73M | 0.1% | History |
| QUREuniQure N.V. | SHS | 50,000 | $1.20M | 0.1% | History |
| FRNMFreenome, Inc. | CL A ORD SHS | 50,000 | $651.5K | <0.1% | History |